244 related articles for article (PubMed ID: 33656136)
21. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
22. Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis.
Wigg de Araújo Lagos L; de Jesus Lopes de Abreu A; Caetano R; Braga JU
J Travel Med; 2023 Apr; 30(2):. PubMed ID: 35947986
[TBL] [Abstract][Full Text] [Related]
23. Suspected YF-AND after yellow fever vaccination in Finland.
Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
[TBL] [Abstract][Full Text] [Related]
24. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
[TBL] [Abstract][Full Text] [Related]
25. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
[TBL] [Abstract][Full Text] [Related]
26. Yellow fever vaccine: an effective vaccine for travelers.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
[TBL] [Abstract][Full Text] [Related]
27. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases.
Pileggi GS; Da Mota LMH; Kakehasi AM; De Souza AW; Rocha A; de Melo AKG; da Fonte CAM; Bortoletto C; Brenol CV; Marques CDL; Zaltman C; Borba EF; Reis ER; Freire EAM; Klumb EM; Christopoulos GB; Laurindo IMM; Ballalai I; Da Costa IP; Michelin L; de Azevêdo Valadares LD; Chebli LA; Lacerda M; Toscano MAF; Yazbek MA; De Abreu Vieira RMR; Magalhães R; Kfouri R; Richtmann R; Merenlender SDCS; Valim V; De Assis MR; Kowalski SC; Trevisani VFM
Adv Rheumatol; 2019 Apr; 59(1):17. PubMed ID: 31036077
[TBL] [Abstract][Full Text] [Related]
28. A public health risk assessment for yellow fever vaccination: a model exemplified by an outbreak in the state of São Paulo, Brazil.
Ribeiro AF; Tengan C; Sato HK; Spinola R; Mascheretti M; França AC; Port-Carvalho M; Pereira M; Souza RP; Amaku M; Burattini MN; Coutinho FA; Lopez LF; Massad E
Mem Inst Oswaldo Cruz; 2015 Apr; 110(2):230-4. PubMed ID: 25946247
[TBL] [Abstract][Full Text] [Related]
29. Yellow Fever outbreaks in unvaccinated populations, Brazil, 2008-2009.
Romano AP; Costa ZG; Ramos DG; Andrade MA; Jayme Vde S; Almeida MA; Vettorello KC; Mascheretti M; Flannery B
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2740. PubMed ID: 24625634
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with severity of adverse events following yellow fever vaccination during the biggest outbreak of the disease recorded in Brazil, 2016-2017.
Lucena ARFP; Souza LRO; Percio J; Carvalho SMD; Romano APM; Domingues CMAS
Epidemiol Serv Saude; 2020; 29(1):e2018331. PubMed ID: 32215531
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
32. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
33. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
[TBL] [Abstract][Full Text] [Related]
34. Epidemiological description of and response to a large yellow fever outbreak in Edo state Nigeria, September 2018 - January 2019.
Nwachukwu William E; Oladejo J; Ofoegbunam CM; Anueyiagu C; Dogunro F; Etiki SO; Dachung BI; Obiekea C; Aderoju B; Akanbi K; Adeyemi IT; Famokun GA; Emelife O; Osamwonyi IW; Ochu CL; Abiode A; Ireye F; Chukwuji M; Ipadeola O; Saiki M; Okudo I; Nwodo D; Oteri JA; Ilori E; Mba N; Ihekweazu C
BMC Public Health; 2022 Aug; 22(1):1644. PubMed ID: 36042438
[TBL] [Abstract][Full Text] [Related]
35. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
[TBL] [Abstract][Full Text] [Related]
36. Advanced age a risk factor for illness temporally associated with yellow fever vaccination.
Martin M; Weld LH; Tsai TF; Mootrey GT; Chen RT; Niu M; Cetron MS;
Emerg Infect Dis; 2001; 7(6):945-951. PubMed ID: 11747720
[TBL] [Abstract][Full Text] [Related]
37. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
38. Age-related risk of adverse events following yellow fever vaccination in Australia.
Lawrence GL; Burgess MA; Kass RB
Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963
[TBL] [Abstract][Full Text] [Related]
39. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
40. [Yellow fever vaccination: update on rare and severe adverse effects].
Receveur MC; Bruyand M; Pistone T; Malvy D
Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
